BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8823253)

  • 1. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival.
    Poen JC; Hoppe RT; Horning SJ
    Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):3-12. PubMed ID: 8823253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group.
    Tsang RW; Gospodarowicz MK; Sutcliffe SB; Crump M; Keating A
    Eur J Cancer; 1999 Jan; 35(1):73-8. PubMed ID: 10211091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
    Chopra R; McMillan AK; Linch DC; Yuklea S; Taghipour G; Pearce R; Patterson KG; Goldstone AH
    Blood; 1993 Mar; 81(5):1137-45. PubMed ID: 8443375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease.
    Fleury J; Legros M; Colombat P; Cure H; Travade P; Tortochaux J; Dionet C; Chollet P; Linassier C; Lamagnere JP; Blaise D; Viens P; Maraninchi D; Plagne R
    Leuk Lymphoma; 1996 Jan; 20(3-4):259-66. PubMed ID: 8624465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.
    Nademanee A; Molina A; Fung H; Stein A; Parker P; Planas I; O'Donnell MR; Snyder DS; Kashyap A; Spielberger R; Bhatia R; Krishnan A; Sniecinski I; Vora N; Slovak M; Dagis A; Niland JC; Forman SJ
    Biol Blood Marrow Transplant; 1999; 5(5):292-8. PubMed ID: 10534059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.
    Armitage JO; Bierman PJ; Vose JM; Anderson JR; Weisenburger DD; Kessinger A; Reed EC; Vaughan WP; Coccia PF; Purtilo DT
    Am J Med; 1991 Dec; 91(6):605-11. PubMed ID: 1750430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
    Seymour LK; Dansey RD; Bezwoda WR
    Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.